Selenium for the prevention of cutaneous melanoma

Nutrients

Volumn 5, Issue 3, 2013, Pages 725-749

  Cassidy, Pamela B ^a,b   Fain, Heidi D ^b   Cassidy, James P ^b   Tran, Sally M ^b   Moos, Philip J ^c   Boucher, Kenneth M ^a   Gerads, Russell ^d   Florell, Scott R ^b   Grossman, Douglas ^b   Leachman, Sancy A ^b  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Applied Speciation   (United States)

Author keywords

HGF mouse; Melanoma; Methylseleninic acid; Selenium; Selenomethionine

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; CASPASE 3; CASPASE 9; GLUCOSE REGULATED PROTEIN 78; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; MATRIX METALLOPROTEINASE; METHYLSELENINIC ACID; OSTEONECTIN; PROTEIN IRE1; SCATTER FACTOR; SELENIUM DERIVATIVE; SELENOMETHIONINE; TUBULIN; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; CUTANEOUS MELANOMA; DIET SUPPLEMENTATION; DISEASE MODEL; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; FOOD COMPOSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA CELL; MOUSE; NONHUMAN; NUTRITIONAL STATUS; OXIDATIVE STRESS; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ULTRAVIOLET RADIATION; UNFOLDED PROTEIN RESPONSE;

EID: 84875077069     PISSN: 20726643     EISSN: None     Source Type: Journal    
DOI: 10.3390/nu5030725     Document Type: Article

References (65)

1. Schrauzer, G.N.; Surai, P.F. Selenium in human and animal nutrition: Resolved and unresolved issues. Crit. Rev. Biotechnol. 2009, 29, 2-9
2. Zhang, Y.; Zhou, Y.; Schweizer, U.; Savaskan, N.E.; Hua, D.; Kipnis, J.; Hatfield, D.L.; Gladyshev, V.N. Comparative analysis of selenocysteine machinery and selenoproteome gene expression in mouse brain identifies neurons as key functional sites of selenium in mammals. J. Biol. Chem. 2008, 283, 2427-2438
3. Walshe, J.; Serewko-Auret, M.M.; Teakle, N.; Cameron, S.; Minto, K.; Smith, L.; Burcham, P.C.; Russell, T.; Strutton, G.; Griffin, A.;et al. Inactivation of glutathione peroxidase activity contributes to UV-induced squamous cell carcinoma formation. Cancer Res. 2007, 67, 4751-4758
4. Wenk, J.; Schuller, J.; Hinrichs, C.; Syrovets, T.; Azoitei, N.; Podda, M.; Wlaschek, M.; Brenneisen, P.; Schneider, L.A.; Sabiwalsky, A.;et al. Overexpression of phospholipid-hydroperoxide glutathione peroxidase in human dermal fibroblasts abrogates uva irradiation-induced expression of interstitial collagenase/matrix metalloproteinase-1 by suppression of phosphatidylcholine hydroperoxide-mediated nfkappab activation and interleukin-6 release. J. Biol. Chem. 2004, 279, 45634-45642
5. Lee, J.B.; Yun, S.J.; Chae, H.Z.; Won, Y.H.; Kim, Y.P.; Lee, S.C. Expression of peroxiredoxin and thioredoxin in dermatological disorders. Br. J. Dermatol. 2002, 146, 710-712
6. Velicer, C.M.; Ulrich, C.M. Vitamin and mineral supplementation among US adults after cancer diagnosis: A systematic review. J. Clin. Oncol. 2008, 28, 665-673
7. Blot, W.J.; Li, J.Y.; Taylor, P.R.; Guo, W.; Dawsey, S.; Wang, G.Q.; Yang, C.S.; Zheng, S.F.; Gail, M.; Li, G.Y.;et al. Nutrition intervention trials in Linxian, China: Supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl. Cancer Inst. 1993, 85, 1483-1492
8. Clark, L.C.; Combs, G.F., Jr.; Turnbull, B.W.; Slate, E.H.; Chalker, D.K.; Chow, J.; Davis, L.S.; Glover, R.A.; Graham, G.F.; Gross, E.G.;et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: A randomized controlled trial. JAMA 1996, 276, 1957-1963
9. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N. Engl. J. Med. 1994, 330, 1029-1035
10. Lippman, S.M.; Goodman, P.J.; Klein, E.A.; Parnes, H.L.; Thompson, I.M., Jr.; Kristal, A.R.; Santella, R.M.; Probstfield, J.L.; Moinpour, C.M.; Albanes D.;et al. Designing the selenium and vitamin E cancer prevention trial (SELECT). J. Natl. Cancer Inst. 2005, 97, 94-102
11. Klein E.A.; Thompson M., Jr.; Tangen C.M.; Crowley J.J.; Lucia M.S.; Goodman P.J.; Minasian L.M. , Ford L.G. , Parnes H.L., Gaziano J.M.;et al. Vitamin E and the risk of prostate cancer: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2011, 306, 1549-1556
12. Gaziano, J.M.; Glynn, R.J.; Christen, W.G.; Kurth, T.; Belanger, C.; MacFadyen, J.; Bubes, V.; Manson, J.E.; Sesso, H.D.; Buring, J.E. Vitamins E and C in the prevention of prostate and total cancer in men: The physicians' health study II randomized controlled trial. JAMA 2009, 301, 52-62
13. Gann, P.H. Randomized trials of antioxidant supplementation for cancer prevention: First bias, now chance-next, cause. JAMA 2009, 301, 102-103
14. Lippman, S.M.; Klein E.A.; Goodman P.J.; Lucia M.S.; Thompson I.M.; Ford L.G.; Parnes H.L.; Minasian L.M.; Gaziano M.; Hartline J.A.;et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA 2009, 301, 39-51
15. Marshall, J.R.; Ip, C.; Romano, K.; Fetterly, G.; Fakih, M.; Jovanovic, B.; Perloff, M.; Crowell, J.; Davis, W.; French-Christy R.;et al. Methyl selenocysteine: Single-dose pharmacokinetics in men. Cancer Prev. Res. 2011, 4, 1938-1944
16. Grossman, D.; Leffell, D.J. The molecular basis of nonmelanoma skin cancer: New understanding. Arch. Dermatol. 1997, 133, 1263-1270
17. Gilchrest, B.A.; Eller, M.S.; Geller, A.C.; Yaar, M. The pathogenesis of melanoma induced by ultraviolet radiation. N. Engl. J. Med. 1999, 340, 1341-1348
18. Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arold, S.T.; Imielinski, M.; Theurillat, J.P.; Nickerson, E.; Auclair, D.; Li, L.; Place, C.;et al. A landscape of driver mutations in melanoma. Cell 2012, 150, 251-263
19. Krauthammer, M.; Kong, Y.; Ha, B.H.; Evans, P.; Bacchiocchi, A.; McCusker, J.P.; Cheng, E.; Davis, M.J.; Goh, G.; Choi, M.;et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 2012, 44, 1006-1014
20. Meyskens, F.L., Jr.; Farmer, P.; Fruehauf, J.P. Redox regulation in human melanocytes and melanoma. Pigment Cell Res. 2001, 14, 148-154
21. Mitra, D.; Luo, X.; Morgan, A.; Wang, J.; Hoang, M.P.; Lo, J.; Guerrero, C.R.; Lennerz, J.K.; Mihm, M.C.; Wargo, J.A.;et al. An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature 2012, 491, 449-453
22. Bruner, S.D.; Norman, D.P.; Verdine, G.L. Structural basis for recognition and repair of the endogenous mutagen 8-oxoguanine in DNA. Nature 2000, 403, 859-866
23. Katiyar, S.K.; Afaq, F.; Perez, A.; Mukhtar, H. Green tea polyphenol-epigallocatechin-3-gallate treatment of human skin inhibits ultraviolet radiation-induced oxidative stress. Carcinogenesis 2001, 22, 287-294
24. Cotter, M.A.; Thomas, J.; Cassidy, P.; Robinette, K.; Jenkins, N.; Florell, S.R.; Leachman, S.; Samlowski, W.E.; Grossman, D. N-acetylcysteine protects melanocytes against oxidative stress/damage and delays onset of ultraviolet-induced melanoma in mice. Clin. Cancer Res. 2007, 13, 5952-5958
25. Francis, S.O.; Mahlberg, M.J.; Johnson, K.R.; Ming, M.E.; Dellavalle, R.P. Melanoma chemoprevention. J. Am. Acad. Dermatol. 2006, 55, 849-861
26. Ip, C.; Thompson, H.J.; Zhu, Z.; Ganther, H.E. In vitro and in vivo studies of methylseleninic acid: Evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res. 2000, 60, 2882-2886
27. Menter, D.G.; Sabichi, A.L.; Lippman, S.M. Selenium effects on prostate cell growth. Cancer Epidemiol. Biomark. Prev. 2000, 9, 1171-1182
28. Halaban, R.; Cheng, E.; Zhang, Y.; Moellmann, G.; Hanlon, D.; Michalak, M.; Setaluri, V.; Hebert, D.N. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc. Natl. Acad. Sci. USA 1997, 94, 6210-6215
29. Bennett, D.C.; Cooper, P.J.; Hart, I.R. A line of non-tumorigenic mouse melanocytes, syngeneic with the b16 melanoma and requiring a tumour promoter for growth. Int. J. Cancer 1987, 39, 414-418
30. Zu, K.; Bihani, T.; Lin, A.; Park, Y.M.; Mori, K.; Ip, C. Enhanced selenium effect on growth arrest by BIP/GRP78 knockdown in p53-null human prostate cancer cells. Oncogene 2006, 25, 546-554
31. Jenkins, N.C.; Liu, T.; Cassidy, P.; Leachman, S.A.; Boucher, K.M.; Goodson, A.G.; Samadashwily, G.; Grossman, D. The p16(INK4A) tumor suppressor regulates cellular oxidative stress. Oncogene 2011, 30, 265-274
32. Brigelius-Flohe, R.; Wingler, K.; Muller, C. Estimation of individual types of glutathione peroxidases. Methods Enzymol. 2002, 347, 101-112
33. Goodson, A.G.; Cotter, M.A.; Cassidy, P.; Wade, M.; Florell, S.R.; Liu, T.; Boucher, K.M.; Grossman, D. Use of oral N-acetylcysteine for protection of melanocytic nevi against UV-induced oxidative stress: Towards a novel paradigm for melanoma chemoprevention. Clin. Cancer Res. 2009, 15, 7434-7440
34. Moos, P.J.; Fitzpatrick, F.A. Taxanes propagate apoptosis via two cell populations with distinctive cytological and molecular traits. Cell Growth Differ. 1998, 9, 687-697
35. Noonan, F.P.; Dudek, J.; Merlino, G.; De Fabo, E.C. Animal models of melanoma: An HGF/SF transgenic mouse model may facilitate experimental access to uv initiating events. Pigment Cell Res. 2003, 16, 16-25
36. Grossman, D.; Kim, P.J.; Schechner, J.S.; Altieri, D.C. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA 2001, 98, 635-640
37. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2011
38. Ip, C.; Dong, Y.; Ganther, H.E. New concepts in selenium chemoprevention. Cancer Metastasis Rev. 2002, 21, 281-289
39. Short, M.D.; Xie, Y.; Li, L.; Cassidy, P.B.; Roberts, J.C. Characteristics of selenazolidine prodrugs of selenocysteine: Toxicity and glutathione peroxidase induction in V79 cells. J. Med. Chem. 2003, 46, 3308-3313
40. Moos, P.J.; Edes, K.; Cassidy, P.; Massuda, E.; Fitzpatrick, F.A. Electrophilic prostaglandins and lipid aldehydes repress redox-sensitive transcription factors p53 and hypoxia-inducible factor by impairing the selenoprotein thioredoxin reductase. J. Biol. Chem. 2003, 278, 745-750
41. Cassidy, P.B.; Edes, K.; Nelson, C.C.; Parsawar, K.; Fitzpatrick, F.A.; Moos, P.J. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis 2006, 27, 2538-2549
42. Burke, K.E.; Combs, G.F., Jr.; Gross, E.G.; Bhuyan, K.C.; Abu-Libdeh, H. The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation. Nutr. Cancer 1992, 17, 123-137
43. Novoselov, S.V.; Calvisi, D.F.; Labunskyy, V.M.; Factor, V.M.; Carlson, B.A.; Fomenko, D.E.; Moustafa, M.E.; Hatfield, D.L.; Gladyshev, V.N. Selenoprotein deficiency and high levels of selenium compounds can effectively inhibit hepatocarcinogenesis in transgenic mice. Oncogene 2005, 24, 8003-8011
44. Jiang, C.C.; Chen, L.H.; Gillespie, S.; Kiejda, K.A.; Mhaidat, N.; Wang, Y.F.; Thorne, R.; Zhang, X.D.; Hersey, P. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 2007, 67, 5880-5888
45. Li, H.; Zhu, H.; Xu, C.J.; Yuan, J. Cleavage of bid by caspase 8 mediates the mitochondrial damage in the fas pathway of apoptosis. Cell 1998, 94, 491-501
46. Ikuta, Y.; Nakatsura, T.; Kageshita, T.; Fukushima, S.; Ito, S.; Wakamatsu, K.; Baba, H.; Nishimura, Y. Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clin. Cancer Res. 2005, 11, 8079-8088
47. Ledda, M.F.; Adris, S.; Bravo, A.I.; Kairiyama, C.; Bover, L.; Chernajovsky, Y.; Mordoh, J.; Podhajcer, O.L. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 1997, 3, 171-176
48. Juliger, S.; Goenaga-Infante, H.; Lister, T.A.; Fitzgibbon, J.; Joel, S.P. Chemosensitization of B-cell lymphomas by methylseleninic acid involves nuclear factor-kappab inhibition and the rapid generation of other selenium species. Cancer Res. 2007, 67, 10984-10992
49. McClung, H.M.; Thomas, S.L.; Osenkowski, P.; Toth, M.; Menon, P.; Raz, A.; Fridman, R.; Rempel, S.A. SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neurosci. Lett. 2007, 419, 172-177
50. Rizki, A.; Weaver, V.M.; Lee, S.Y.; Rozenberg, G.I.; Chin, K.; Myers, C.A.; Bascom, J.L.; Mott, J.D.; Semeiks, J.R.; Grate, L.R.;et al. A human breast cell model of preinvasive to invasive transition. Cancer Res. 2008, 68, 1378-1387
51. Scid mice overview. Available online: http://jaxmice.jax.org/support/straindata/scid.html (accessed on 26 February 2013).
52. Burk, R.F.; Norsworthy, B.K.; Hill, K.E.; Motley, A.K.; Byrne, D.W. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol. Biomark. Prev. 2006, 15, 804-810
53. Wang, L.; Bonorden, M.J.; Li, G.X.; Lee, H.J.; Hu, H.; Zhang, Y.; Liao, J.D.; Cleary, M.P.; Lu, J. Methyl-selenium compounds inhibit prostate carcinogenesis in the transgenic adenocarcinoma of mouse prostate model with survival benefit. Cancer Prev. Res. 2009, 2, 484-495
54. Li, G.X.; Lee, H.J.; Wang, Z.; Hu, H.; Liao, J.D.; Watts, J.C.; Combs, G.F., Jr.; Lu, J. Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008, 29, 1005-1012
55. Syed, D.N.; Mukhtar, H. Botanicals for the prevention and treatment of cutaneous melanoma. Pigment Cell Melanoma Res. 2011, 24, 688-702
56. Jackson, M.I.; Combs, G.F. Jr. Selenium and anticarcinogenesis: Underlying mechanisms. Curr. Opin. Clin. Nutr. Metab. Care 2008, 11, 718-726
57. Ip, C. Lessons from basic research in selenium and cancer prevention. J. Nutr. 1998, 128, 1845-1854
58. Pinto, J.T.; Lee, J.I.; Sinha, R.; Macewan, M.E.; Cooper, A.J. Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids 2011, 41, 29-41
59. Ahonen, M.; Poukkula, M.; Baker, A.H.; Kashiwagi, M.; Nagase, H.; Eriksson, J.E.; Kahari, V.M. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003, 22, 2121-2134
60. Chetty, C.; Bhoopathi, P.; Lakka, S.S.; Rao, J.S. MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line. Oncogene 2007, 26, 7675-7683
61. Reid, M.E.; Stratton, M.S.; Lillico, A.J.; Fakih, M.; Natarajan, R.; Clark, L.C.; Marshall, J.R. A report of high-dose selenium supplementation: Response and toxicities. J. Trace Elem. Med. Biol. 2004, 18, 69-74
62. Reagan-Shaw, S.; Nihal, M.; Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22, 659-661
63. Hurst, R.; Armah, C.N.; Dainty, J.R.; Hart, D.J.; Teucher, B.; Goldson, A.J.; Broadley, M.R.; Motley, A.K.; Fairweather-Tait, S.J. Establishing optimal selenium status: Results of a randomized, double-blind, placebo-controlled trial. Am. J. Clin. Nutr. 2010, 91, 923-931
64. Johnson, W.D.; Morrissey, R.L.; Kapetanovic, I.; Crowell, J.A.; McCormick, D.L. Subchronic oral toxicity studies of se-methylselenocysteine, an organoselenium compound for breast cancer prevention. Food Chem. Toxicol. 2008, 46, 1068-1078
65. Zhang, J.; Wang, L.; Li, G.; Anderson, L.B.; Xu, Y.; Witthuhn, B.; Lu, J. Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. Nutr. Cancer 2011, 63, 778-789.